[{"orgOrder":0,"company":"RenovaCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Tissue-Specific Pluripotent Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"RenovaCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"RenovaCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RenovaCare \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by RenovaCare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          World Vape Show
                          Not Confirmed
                          World Vape Show
                          Not Confirmed

                          Details : RenovaCare is currently developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

                          Product Name : CellMist

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          July 22, 2021

                          Lead Product(s) : Tissue-Specific Pluripotent Cell

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank